AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Aura Biosciences, Inc.
Video analysis: AURA
All videosNo video analysis for this stock yet. Request one from our team.
News: AURA
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) by 39.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,100,000 shares of the company's stock after purchasing an additional 2,000,000 shares during the quarter. Aura
Aura Biosciences to Participate in Upcoming Investor Conference
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,707,674 shares of the company's stock, valued at approximately $33,424,000. BlackRock Inc. owned approximately 4.55% of
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,152 shares of the company's stock, valued at approximately $924,000. ADAR1 Capital Management LLC
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.
